Fraunhofer Institute for Cell Therapy and Immunology IZI

NEW & EMERGING TECHNOLOGIES

September 11–13, 2017 | Fraunhofer-Konferenzzentrum Potsdam-Golm, Germany

more info

Fraunhofer Life Science Symposium 2017

November 8–9, 2017 | Fraunhofer IZI Leipzig, Germany

more info

18th International Symposium on Albumin Dialysis (ISAD)

September 8–10, 2017 | Rostock-Hohe Düne, Germany

more info

Recognising dyslexia in time: Foundations laid for future early test

Press information | 20.7.2017

more info

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering.

One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology.

Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation.

In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Business units

Jobs / career

Press

Publications

News

 

Press information / 20.7.2017

Recognising dyslexia in time: Foundations laid for future early test

Five years of common research has made it possible: An early test which recognises widespread dyslexia in time–and would therefore spare about five per cent of children a long path of suffering. Scientists at the Max Planck Institute for Human Cognitive and Brain Sciences and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) have succeeded in laying the foundations for a test which, with the help of brain activity and gene analyses, could predict whether a child could be affected by this disorder. The conclusion of their research project LEGASCREEN offers an opportunity to reflect on current and future dyslexia diagnosis.the Bill & Melinda Gates Foundation.

 

Press information / 1.3.2017

Cooperation between Fraunhofer IZI and Lipocalyx GmbH to develop new carrier systems for the genebased treatment of inflammatory diseases

Press information / 2.2.2017

Fraunhofer IZI and Immunic GmbH carry out joint research on new drugs for treating autoimmune diseases

Since January 2017, researchers from Immunic GmbH have been working with scientists at the Department of Drug Design and Target Validation of the Fraunhofer IZI in Halle (Saale) on developing new drugs. The aim is the preclinical development of one or several active candidate ingredients for treating chronically inflammatory and autoimmune diseases.

Press information / 11.11.2016

How to make hard substrates out of soft ingredients – new research findings could revolutionize stem cell technology

Physicists at Leipzig's Fraunhofer Institute for Cell Therapy and Immunology and Leipzig University have found and characterized innovative materials which may be used as adaptive substrates in cell therapy. In their research, the scientists used synthetic DNA tubes to specifically modify the mechanics of polymer networks. The scientists published their findings in the renowned specialist journal Physical Review Letters.

Contact

Fraunhofer IZI

 

Perlickstraße 1
04103 Leipzig
Germany

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000
E-mail info@izi.fraunhofer.de

 

 

Social Media